Williamson Legacy Group LLC reduced its stake in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 74.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,196 shares of the medical instruments supplier’s stock after selling 3,473 shares during the quarter. Williamson Legacy Group LLC’s holdings in Insulet were worth $340,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after acquiring an additional 87,845 shares during the last quarter. Northern Trust Corp increased its stake in Insulet by 0.5% during the third quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock worth $218,945,000 after acquiring an additional 3,618 shares during the last quarter. Qube Research & Technologies Ltd increased its stake in Insulet by 37.3% during the third quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock worth $177,324,000 after acquiring an additional 156,009 shares during the last quarter. Nordea Investment Management AB increased its stake in Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after acquiring an additional 142,922 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Insulet by 0.8% during the third quarter. Ameriprise Financial Inc. now owns 494,712 shares of the medical instruments supplier’s stock worth $152,703,000 after acquiring an additional 4,057 shares during the last quarter.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on PODD shares. Wells Fargo & Company reduced their price objective on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Stifel Nicolaus reduced their price objective on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Canaccord Genuity Group reduced their price objective on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Truist Financial cut their target price on Insulet from $315.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, Barclays cut their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $253.87.
Insulet Trading Down 0.7%
PODD opened at $153.80 on Wednesday. The stock has a market cap of $10.65 billion, a price-to-earnings ratio of 35.77, a P/E/G ratio of 1.23 and a beta of 1.20. The stock’s 50 day moving average price is $188.59 and its 200-day moving average price is $248.51. Insulet Corporation has a one year low of $145.59 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.
Insulet (NASDAQ:PODD – Get Free Report) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s quarterly revenue was up 33.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts forecast that Insulet Corporation will post 6.43 EPS for the current year.
About Insulet
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
See Also
- Five stocks we like better than Insulet
- AI Can’t Reach the Real World Without These 3 Stocks
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
